Entelos applies biosimulation, virtual patient capability.

Entelos and Organon extended their ongoing rheumatoid arthritis collaboration.

“Organon was one of the first companies to recognize the potential impact of Entelos’ biosimulation capability and therapeutic expertise,” states James Karis, president and CEO of Entelos. 

In silico R&D is a predictive research method aimed at increasing efficiency and productivity across the entire drug discovery and development pipeline. Using virtual patients and virtual drugs and targets, experiments are simulated, rapidly testing what would otherwise take months or years to do in the laboratory or clinic.

Previous articleSmartGene and LabCorp Partner to Hasten Bacterial and Fungal Pathogen ID
Next articleMerck KGaA and Nano Terra Embark on Nanotechnology Alliance